文献速递肾癌与肾肿瘤

肠道菌群组成驱动肾细胞癌患者对癌症免疫治疗的原发耐药

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
PubMed 文献 · Eur Urol · 2020-05-04

该研究前瞻性收集69例接受纳武利尤单抗治疗的晚期肾细胞癌(RCC)患者粪便,采用全基因组测序宏基因组分析,发现近期抗生素使用降低客观缓解率(从28%降至9%,p<0.03)并改变菌群组成;小鼠粪菌移植实验证实菌群组成与免疫检查点阻断(ICB)疗效存在因果关系。

要点

  • 近期抗生素使用降低RCC患者ICB客观缓解率并改变菌群组成。
  • 特定菌种如Clostridium hathewayi在RCC患者粪便中富集。
  • 粪菌移植小鼠实验支持菌群组成与ICB疗效的因果关系。

核心结论

  • 肠道菌群组成受酪氨酸激酶抑制剂(TKI)和抗生素影响,并影响免疫治疗成功率。

研究设计与样本

  • 前瞻性收集69例接受纳武利尤单抗治疗的晚期RCC患者粪便样本,并分析2994份健康志愿者粪便样本。
  • 在RCC荷瘤小鼠中进行粪菌移植(FMT)临床前研究,使用耐药患者粪便(NR-FMT)。

主要发现

  • 近期抗生素使用(n=11;16%)使客观缓解率从28%降至9%(p<0.03)。
  • 抗生素使用促进Clostridium hathewayi等菌种优势,这些菌种在RCC患者粪便中较健康志愿者更常过表达。
  • 纳武利尤单抗前使用TKI影响菌群组成。
  • NR-FMT小鼠通过接受应答患者FMT或有益共生菌(Akkermansia muciniphila和Bacteroides salyersiae)得到补偿。

临床怎么用

  • 未来可探索补充益生菌以预防免疫治疗原发耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of immune checkpoint blockade (ICB) has revolutionized the clinical outcome of renal cell carcinoma (RCC). Nevertheless, improvement of durability and prediction of responses remain unmet medical needs. While it has been recognized that antibiotics (ATBs) decrease the clinical activity of ICB across various malignancies, little is known about the direct impact of distinct intestinal nonpathogenic bacteria (commensals) on therapeutic outcomes of ICB in RCC. OBJECTIVE: To evaluate the predictive value of stool bacteria composition for ICB efficacy in a cohort of advanced RCC patients. DESIGN, SETTING, AND PARTICIPANTS: We prospectively collected fecal samples from 69 advanced RCC patients treated with nivolumab and enrolled in the GETUG-AFU 26 NIVOREN microbiota translational substudy phase 2 trial (NCT03013335) at Gustave Roussy. We recorded patient characteristics including ATB use, prior systemic therapies, and response criteria. We analyzed 2994 samples of feces from healthy volunteers (HVs). In parallel, preclinical studies performed in RCC-bearing mice that received fecal transplant (FMT) from RCC patients resistant to ICB (NR-FMT) allowed us to draw a cause-effect relationship between gut bacteria composition and clinical outcomes for ICB. The influence of tyrosine kinase inhibitors (TKIs) taken before starting nivolumab on the microbiota composition has also been assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metagenomic data (MG) from whole genome sequencing (WGS) were analyzed by multivariate and pairwise comparisons/fold ratio to identify bacterial fingerprints related to ATB or prior TKI exposure and patients' therapeutic response (overall response and progression-free survival), and compared with the data from cancer-free donors. RESULTS AND LIMITATIONS: Recent ATB use (n = 11; 16%) reduced objective response rates (from 28% to 9%, p < 0.03) and markedly affected the composition of the microbiota, facilitating the dominance of distinct species such as Clostridium hathewayi, which were also preferentially over-represented in stools from RCC patients compared with HVs. Importantly, TKIs taken prior to nivolumab had implications in shifting the microbiota composition. To establish a cause-effect relationship between gut bacteria composition and ICB efficacy, NR-FMT mice were successfully compensated with either FMT from responding RCC patients or beneficial commensals identified by WGS-MG (Akkermansia muciniphila and Bacteroides salyersiae). CONCLUSIONS: The composition of the microbiota is influenced by TKIs and ATBs, and impacts the success of immunotherapy. Future studies will help sharpen the role of these specific bacteria and their potential as new biomarkers. PATIENT SUMMARY: We used quantitative shotgun DNA sequencing of fecal microbes as well as preclinical models of fecal or bacterial transfer to study the association between stool composition and (pre)clinical outcome to immune checkpoint blockade. Novel insights into the pathophysiological relevance of intestinal dysbiosis in the prognosis of kidney cancer may lead to innovative therapeutic solutions, such as supplementation with probiotics to prevent primary resistance to therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Derosa L, Routy B, Fidelle M, et al. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. Eur Urol. 2020. PMID: 32376136. doi:10.1016/j.eururo.2020.04.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。